These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12522573)

  • 41. Practical importance of neuroprotection in Parkinson's disease.
    Riederer P; Gille G; Müller T; Przuntek H; Reichmann H; Riess O; Schwartz A; Schwarz J; Vogt T
    J Neurol; 2002 Oct; 249 Suppl 3():III/53-6. PubMed ID: 12522574
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
    Dupre KB; Eskow KL; Negron G; Bishop C
    Brain Res; 2007 Jul; 1158():135-43. PubMed ID: 17553470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The rationale for the use of dopamine agonists in Parkinson's disease.
    Jenner P
    Neurology; 1995 Mar; 45(3 Suppl 3):S6-12. PubMed ID: 7715795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute pharmacologic blockade of dyskinesias in Parkinson's disease.
    Blanchet PJ; Metman LV; Mouradian MM; Chase TN
    Mov Disord; 1996 Sep; 11(5):580-1. PubMed ID: 8866502
    [No Abstract]   [Full Text] [Related]  

  • 47. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; Blanchet PJ; van den Munckhof P; Chase TN
    Amino Acids; 1998; 14(1-3):75-82. PubMed ID: 9871445
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New and emerging therapies for Parkinson disease.
    Jankovic J
    Arch Neurol; 1999 Jul; 56(7):785-90. PubMed ID: 10404979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is there neuroprotection in Parkinson syndrome?
    Riederer P; Sian J; Gerlach M
    J Neurol; 2000 Sep; 247 Suppl 4():IV/8-11. PubMed ID: 11199820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of Parkinson's disease--from theory to practice].
    Friedman A
    Neurol Neurochir Pol; 1999; 32 Suppl 6():81-90. PubMed ID: 11107568
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cell transplantation for Parkinson's disease.
    Emerich DF
    Cell Transplant; 2002; 11(1):1-3. PubMed ID: 12095215
    [No Abstract]   [Full Text] [Related]  

  • 52. Acupuncture for Parkinson's disease: From theory to practice.
    Fan JQ; Lu WJ; Tan WQ; Feng WC; Zhuang LX
    Biomed Pharmacother; 2022 May; 149():112907. PubMed ID: 35366533
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How to treat Parkinson's disease in 2013.
    Worth PF
    Clin Med (Lond); 2013 Feb; 13(1):93-6. PubMed ID: 23472504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of Parkinson's disease: an evidence-based review.
    Mov Disord; 2002; 17 Suppl 4():S1-166. PubMed ID: 12211134
    [No Abstract]   [Full Text] [Related]  

  • 55. Parkinson's disease. V.A.-D.V.A. Study Group. Part 5. Physiology of the dyskinesias. The role of future drug therapy studies.
    MACINTOSH
    Med Serv J Can; 1960; 16():618-20. PubMed ID: 13853746
    [No Abstract]   [Full Text] [Related]  

  • 56. Evidence-based medicine. Introduction.
    Movement Disorder Society Evidence Based Medicine Task Force on Update of Treatments for Parkinson' Disease
    Mov Disord; 2011 Oct; 26 Suppl 3():S1. PubMed ID: 22021172
    [No Abstract]   [Full Text] [Related]  

  • 57. Adrenoceptor agonists and antagonists and risk of Parkinson's disease.
    Maghzi H; Hogg EJ; Tan E; Pagano G; Tagliati M
    Mov Disord; 2019 Mar; 34(3):442. PubMed ID: 30875150
    [No Abstract]   [Full Text] [Related]  

  • 58. Which factors influence therapeutic decisions in Parkinson's disease?
    Baas H; Fuchs G; Gemende I; Hueber R; Lachenmayer L; Schneider E; Schoenberger B; Werner M
    J Neurol; 2002 Oct; 249 Suppl 3():III/49-52. PubMed ID: 12522573
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dyskinesia in Parkinson's disease. Pathophysiology and clinical risk factors.
    Baas H
    J Neurol; 2000 Sep; 247 Suppl 4():IV/12-6. PubMed ID: 11199809
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.